In addition to mAb and ADCs, another HER-2 targeted therapeutic strategy is blockade of the main cellular pathways leading to the characteristic aggressiveness of HER-2+ BC, such as PI3K/AKT/mTOR and MAPK pathways, by using specific inhibitors. Here, MTOR is linked to breast cancer.